This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) is set to report earnings and revenue figures and provide updates on its pipeline when it releases fourth-quarter 2021 results.
Top Stock Reports for Microsoft, Amazon & Tesla
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Amazon.com, Inc. (AMZN), and Tesla, Inc. (TSLA).
Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mednax (MD) Buys Night Lite Pediatrics to Boost Portfolio
by Zacks Equity Research
Mednax (MD) purchases Night Lite Pediatrics, LLC in Orlando to enhance its pediatric business line.
Sanofi's (SNY) Enjaymo Gets FDA Nod For Rare Blood Disorder
by Zacks Equity Research
The FDA approves Sanofi's (SNY) Enjaymo for the treatment of hemolysis in adult patients with cold agglutinin disease. Enjaymo is the first therapy to be approved for this indication.
The Zacks Analyst Blog Highlights: General Motors Co., Tesla Inc., Marvell Technology Inc., FedEx Corp. and Zoetis Inc
by Zacks Equity Research
General Motors Co., Tesla Inc., Marvell Technology Inc., FedEx Corp. and Zoetis Inc are highlighted in this Analyst Blog article.
Top 5 Stocks to Buy on the Dip Despite Market Fluctuations
by Nalak Das
We have narrowed our search to five U.S. corporate giants (market capital > $50 billion) that are currently trading on the dip. These are: TSLA, GM, FDX, MRVL and ZTS.
Here's Why Seasoned Investors are Retaining Mednax (MD)
by Zacks Equity Research
Banking on its strategic measures and a streamlined business, Mednax (MD) holds potential to reap benefits for investors.
Why Holding Anthem (ANTM) in Your Portfolio is a Prudent Move?
by Zacks Equity Research
Riding high on its strategic measures and a rising membership, Anthem (ANTM) holds prospects to reap benefits for investors.
Here's Why Zoetis (ZTS) is Poised for a Turnaround After Losing 8.8% in 4 Weeks
by Zacks Equity Research
Zoetis (ZTS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
CORT vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
CORT vs. ZTS: Which Stock Is the Better Value Option?
JAZZ's Xywav Gets Orphan Drug Exclusivity for Hypersomnia
by Zacks Equity Research
The FDA bestows an Orphan Drug Exclusivity to Jazz's (JAZZ) Xywav for treating idiopathic hypersomnia in adults. This is the second Orphan Drug Exclusivity for the drug.
Acadia Healthcare (ACHC) Buys Real Estate to Expand in Chicago
by Zacks Equity Research
Acadia Healthcare (ACHC) purchases real estate in Illinois to serve the local communities with better healthcare facilities.
Ensign Group (ENSG) Hikes Dividend to Share More Profits
by Zacks Equity Research
Ensign Group's (ENSG) dividend hike reflects its intention to enhance shareholders' value supported by its strong financial position.
The Zacks Analyst Blog Highlights: Walmart, Honeywell, Zoetis, Colgate-Palmolive and IDEXX Lab
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Walmart, Honeywell, Zoetis, Colgate-Palmolive and IDEXX Lab
Top Stock Reports for Walmart, Honeywell & Zoetis
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), Honeywell International Inc. (HON), and Zoetis Inc. (ZTS).
Zoetis' (ZTS) Earnings and Revenues Surpass Estimates in Q3
by Kanishka Das
Zoetis' (ZTS) earnings and revenues beat estimates in the third quarter of 2021. The company raised its financial guidance for 2021.
Zoetis (ZTS) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 13.64% and 2.74%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Drug, Biotech Stock Q3 Earnings on Nov 4: MRNA, REGN & More
by Zacks Equity Research
Let us take a look at five drug/biotech companies due to release their quarterly results on Nov 4.
Is a Surprise Coming for Zoetis (ZTS) This Earnings Season?
by Zacks Equity Research
Zoetis (ZTS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Viatris (VTRS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Viatris' (VTRS) Q3 earnings might have gained from the solid performance of Viagra, Dymista, and the Thrombosis portfolio.
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
by Zacks Equity Research
Zoetis (ZTS) is set to report earnings and revenues, and provide updates on its diversified product portfolio when it releases third-quarter 2021 results.
Humana (HUM) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Humana's (HUM) third-quarter earnings are expected to have gained from higher revenues and a solid contribution from its Retail and Healthcare Services segments.
4 Big Drug, Biotech Stocks Set to Beat Q3 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.